Waunakee, Wis. — Scientific Protein Laboratories, a producer of active pharmaceutical ingredients (API), was acquired by New York-based Arsenal Capital Partners.
Arsenal, which targets specialty manufacturing, specialty chemicals and healthcare companies announced the acquisition, which is valued at $81 million, today.
SPL, based in Waunakee, Wis., is the world’s largest independent producer of heparin API, which is used to manufacture anticoagulants used in the prevention and treatment of thrombosis, embolism, acute coronary syndromes and surgical recoveries involving implants. SPL also manufactures pancreatin API, which is used to treat pancreatic deficiency of cystic fibrosis and a variety of digestive disorders.
“We look forward to working with the Arsenal Capital team to invest in our existing businesses as well as pursue new opportunities within the carbohydrate and natural protein product areas,” said David Strunce, president of SPL.